Highlights of breast cancer advances at the ESMO Congress.
Naveed Saleh, MD, MS
The US Food and Drug Administration recently approved alpelisib plus fulvestrant for the treatment of metastatic or otherwise advanced breast cancer.
Researchers look at cost estimates stratified by stage, histology, and level of treatment.
This year has seen many advances in immunotherapy. Here is a look at some of the most significant research.
A review of recent advances in the noninvasive imaging of immunotherapeutic targets.
Researchers report on the BRIGHT AML 1019 Phase III trial.
Researchers explore the predictive capability of EVI1 expression.
Genetic profiles of thyroid cancer shed light on molecular mechanisms.
Researchers look at how mutation status can influence responses to targeted therapy in thyroid cancer.
Investigators assessed effects of TIB on cell number, migration, invasion, estrogen, and progesterone receptor activity and content.